Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C26H28N4O3 and a molecular weight of approximately 444.5 g/mol[6][1]. It is listed in chemical and pharmaceutical databases such as PubChem (CID 25155578), DrugBank (DB08738), and ChEMBL (CHEMBL459149)[6][1]. The structure features a quinoxalinone core substituted with phenyl and pyrrolidine-containing side chains. According to available data, it belongs to the class of alpha amino acid amides[6]. There is no evidence that this compound has been approved for clinical use; it appears to be an experimental or research molecule. No specific mechanism of action, biological target, or therapeutic indication has been established in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one.